Responses
Oral Presentations
Abstract session: Novel treatment in SLE and Sjögren’s syndrome
OP0112 Abatacept Treatment Reduces Disease Activity in Early Primary Sjögren’s Syndrome (Phase II Open Label Asap Study)
Compose a Response to This Article
Other responses
No responses have been published for this article.